Onera Health provides end-to-end polysomnography-as-a-service that enables clinicians to conduct clinical-grade sleep studies in patients' homes or in labs. The company has secured regulatory clearance from the U.S. FDA for its current system. Clinicians order a PSG study, Onera ships four wireless sensors (forehead, upper chest, abdominal area and lower leg) to the patient, then processes the returned hardware and cloud data to produce a report for clinician review. Onera currently serves the Benelux and DACH regions. The company plans to expedite regulatory clearance for a second-generation PSG system in the U.S. and Europe and will continue investing in R&D, customer success, and geographic expansion. Since founding in 2017, Onera has raised €55 million in total and recently added €30 million in a Series C. Onera Health develops sleep diagnostic and remote monitoring solutions, including an innovative polysomnography (PSG) system that recently obtained CE mark. Led by founder/CTO/interim CEO Ruben de Francisco, the company offers diagnostics and remote monitoring services aimed at people with sleep-related ailments and other chronic conditions. Onera recently relocated its headquarters to the Brainport region in Eindhoven while maintaining commercial operations in the United States. The company intends to use new funding to execute clinical studies and further commercialize its sleep diagnostics and monitoring products in Europe and the U.S. Its products are positioned to improve patient health and quality of life by enabling remote monitoring across multiple medical fields. Onera Health is a Palo Alto, CA‑based provider of sleep diagnostic solutions and services and a spin‑off of imec. Its core product uses two simple patches to replace sensors normally attached to the face, scalp, chest and limbs, aiming to deliver test results that match the accuracy of conventional in‑lab sleep clinics. The system enables patients to be monitored at home or in a medical setting suggested by their doctor. Onera has R&D offices in the Netherlands and plans to launch pilot programs with leaders in sleep medicine, including pulmonologists, neurologists, psychiatrists, ENTs, pediatricians and the military. Financially, the company announced it raised more than $9.3M in a Series A financing. The team includes CEO & co‑founder Raphael Michel, CTO & co‑founder Ruben de Francisco, CMO Hartmut Schneider, and other named co‑founders.

Total raised

$55M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2024